학술논문
What Clinicians Need to Know About the Development of Long-Acting Formulations.
Document Type
Article
Source
Subject
*HEPATITIS C prevention
*HIV prevention
*TUBERCULOSIS prevention
*DRUG therapy for tuberculosis
*DRUG approval
*HIV infections
*COMMUNICABLE diseases
*HEPATITIS C
*DRUG administration
*ENDOWMENT of research
*CONTROLLED release preparations
*DRUG stability
*DRUG development
*PHARMACEUTICAL chemistry
*STERILIZATION (Disinfection)
*DRUG side effects
*DRUG resistance in microorganisms
*CHRONIC hepatitis B
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
An introduction is presented in which the author discusses various topics within the issue, including the long-acting (LA) formulations for treating infectious diseases, the approved LA products like LA-rilpivirine, and the LA Extended-Release Antiretroviral Research Resource Program (LEAP).